Delving into the Latest Updates on Acetaminophen with Synapse

Overview

Basic Info

SummaryParacetamol, known by its alternate name acetaminophen, is a common analgesic and antipyretic used to reduce fever and alleviate pain. Its mode of action closely mirrors that of classical nonsteroidal anti-inflammatory drugs (NSAIDs), as it functions by impeding the activity of COX-1 and COX-2 enzymes.Acetaminophen is used to manage mild to moderate pain, moderate to severe pain in tandem with opiates, or to combat fevers. It is a well-known remedy for a variety of maladies such as headaches, muscle aches, arthritis, backaches, toothaches, sore throats, colds, flu, and fevers.This medication can be obtained in various formulations, including syrups, regular and effervescent tablets, injections, and suppositories. Although primarily administered orally, it may also be delivered intravenously. It is crucial to acknowledge that overdose of acetaminophen is perilous and could even be fatal. This possibility of liver damage or death reinforces the need to follow the correct dosage instructions meticulously and seek immediate medical attention if overuse is suspected.Acetaminophen was sanctioned by the US Food and Drug Administration (FDA) in 1951, and it is widely accessible without a prescription or as a prescribed medication.

Drug Type

Small molecule drug

Synonyms

4'-hydroxyacetanilide, 4-(Acetylamino)phenol, 4-ACETAMIDOPHENOL

+ [90]

Target

COX

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

HeadacheAnalgesiaFever+ [1]

Inactive Indication

Acute migraineAcute PainAnesthesia+ [18]

Originator Organization

Dandong Yichang Pharmaceutical Co., Ltd.

Active Organization

Fresenius Kabi USA LLC

Terumo Corp.Viatris Pharmaceutical GK

+ [12]

Inactive Organization

Cosette Pharmaceuticals, Inc.Startup

Merck Sharp & Dohme Corp.AlzProtect SAS

+ [14]

Drug Highest PhaseApproved

First Approval Date

CN (01 Jan 1966),

FeverPain

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC8H9NO2

InChIKeyRZVAJINKPMORJF-UHFFFAOYSA-N

CAS Registry103-90-2

Sleep disturbances, cognitive reserve, and continuing pain and inflammation are other risk factors contributing to delirium (confusion and agitation) and neurocognitive decline (in the long term) following heart surgery. Investigators aim to test a bundle of sleep optimization, cognitive exercise before surgery, and extended pain relief for 48 hours with intravenous acetaminophen combined with enhanced recovery after surgery protocols (SCOPE bundle). SCOPE will fill significant gaps in evidence by testing the value of a patient and care-provider-focused intervention that can potentially minimize POD and improve outcomes (cognitive & physical function, sleep quality, pain, depression or anxiety, and survival) important to patients and families.
The SCOPE trial will address many heart surgery outcome-related questions commonly asked by patients:
What can I do to reduce my chances of developing confusion, hallucinations, or delirium after surgery? How can I best prepare before surgery to improve my long-term health and avoid disability? Are there exercises I can participate in that improve my sleep, pain, and mood after surgery? Intellectual pursuits, physical activity, and social interactions support cognitive reserve, while poor health, poor sleep hygiene, poor nutrition, and mental health disease can diminish reserve. Various interventions with different intensities and timing to augment cognitive reserve have been associated with positive outcomes on neuropsychological testing. Adaptive video gaming for as little as 10 hours leads to the maintenance of independence in activities of daily living and sustained improvements in speed of processing, attention, and working memory in older people. Likely through the increased cognitive reserve, perioperative brain exercise aims to protect against morbid cognitive recovery after surgery.
Sleep is vital for memory and cognitive function. Poor sleep traits in older adults that are potentially modifiable, including short/long duration, daytime napping, and associated sleepiness, led to an almost 2-fold increase in delirium risk. Patients will complete an evidence-based course on healthy sleep habits and will complete guided exercises designed to restructure behaviors and thinking. They are encouraged to follow a set of recommendations to improve their sleep (e.g., optimal sleep duration, advice for habits such as daytime napping, maintaining a regular sleep schedule, avoiding caffeine, regular daylight exposure, dimming lights or electronics and relaxation and thought exercises for optimal sleep); many of these sleep behaviors have been strongly linked to increased risk for cognitive decline. Investigators propose that sleep optimization before AND after (an established best practice sleep bundle) surgical insult will contribute to cognitive reserve leading to decreased delirium risk and key patient-centered outcomes (postoperative sleep, pain, cognition, mood, and survival).
Inadequate pain relief and opioids are both risk factors for delirium. Surgery on the chest is a significant pain source. Approximately 30-75% of patients suffer from moderate to severe pain in the postoperative period. Almost half of the patients have severe pain at rest, and three-quarters have severe pain during coughing and movement. Pain and inflammation are closely biochemically linked.
Sleep, brain exercise, and adequate pain control with opioid-sparing can be additive or synergistic interventions to prevent delirium following heart surgery.
Investigators propose three specific aims by conducting a 1:1 randomized controlled trial in 406 heart surgery patients 60 or older undergoing heart surgery. They will be administered perioperative sleep optimization, brain exercise training, and intravenous acetaminophen over 48 hours. A trained expert will administer the sleep and cognitive exercise protocols at least two weeks before surgery. This expert will handhold the patients for two weeks until the surgery. Thus, the gains made before surgery with better sleep quality and improved brain reserve will be sustained with postoperative pain control to lower the ongoing inflammation. Through this trial, investigators will evaluate if the SCOPE bundle can reduce 1) in-hospital delirium, 2) long-term (one, six, and twelve months) cognitive, physical, and self-care function, and 3) barriers to implementation of this bundle.
Currently, no options are routinely available to patients to optimize their sleep and cognition before cardiac surgery. The proposed research is significant because it will be the first to test the bundled behavioral intervention approach (sleep optimization, brain exercise) before surgery with extended, scheduled pain management with non-opioids following surgery. The SCOPE trial will yield relevant and immediately actionable data to improve care for over 900,000 adults in the U.S. each year.

Start Date01 Feb 2025

Sponsor / Collaborator

Beth Israel Deaconess Medical Center, Inc.

[+3]

NCT06356571

/ Not yet recruitingPhase 2

A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.

Start Date30 Jan 2025

Sponsor / Collaborator

Sanofi

NCT06689943

/ Not yet recruitingPhase 2IIT

Pain After Strabismus Surgery: Post-Operative Outcomes Using Courses of Acetaminophen in Children

At Ann & Robert H. Lurie Children's Hospital of Chicago (Lurie Children's), the current practice is to prescribe children with oral Tylenol as needed every 4-6 hours post strabismus surgery. Prescribing Tylenol "as needed" leaves more room for error for parents to be under-dosing their children, which can lead to avoidable pain. This study aims to figure out if children ages 4-12 years old will feel significantly less pain and discomfort when given regimented Tylenol every 6 hours for 48 hours after strabismus surgery (eye muscle surgery) compared to controls whose parents are instructed to give Tylenol every 4-6 hours as needed for 48 hours after surgery. To date, there have been no studies comparing patient outcomes between those taking Tylenol regimen and those receiving Tylenol as needed after pediatric surgery.

Start Date01 Jan 2025

Sponsor / Collaborator

Ann & Robert H. Lurie Children's Hospital of Chicago

100 Clinical Results associated with Acetaminophen

Login to view more data

100 Translational Medicine associated with Acetaminophen

Login to view more data

100 Patents (Medical) associated with Acetaminophen

Login to view more data

29,237

Literatures (Medical) associated with Acetaminophen

01 May 2025·Atencion Primaria

Article

Author: Gómez-Batiste, Xavier ; Oller Piqué, Ramon ; Serrà Rigol, Thaïs ; Formiguera Macià, Anna ; Casanovas Font, Jordi ; Ballarín Castany, Àngels

OBJECTIVES:

To describe the analgesic treatment of patients with advanced chronic disease (ACD), to determine pain management, and to detect opportunities for improvement.

DESIGN:

Observational, descriptive, cross-sectional, multicentre study.

LOCATION:

Three primary care teams, one intermediate care hospital and five nursing homes in Catalonia.

PARTICIPANTS:

Patients with ACD and pain according to the Brief Pain Inventory (Short Form) scale (or Pain Assessment in Advanced Dementia scale, in case of advanced dementia).

MAIN MEASUREMENTS:

Place of care (home, nursing home, hospital), end of life (EOL) trajectory (organ failure, cancer, dementia, multimorbidity), type of analgesic treatment and pain management according to the Pain Management Index scale.

RESULTS:

The study included 183 patients. The most frequent EOL trajectory was dementia, followed by organ failure, multimorbidity and cancer. The most commonly used analgesic was paracetamol, while weak opioids were testimonial. Analgesic use differed according to EOL trajectory and place of care, with the use of strong opioids prevailing in cancer and hospital, respectively. Almost half of patients had negative PMI, and none non-pharmacological intervention for pain control was recorded.

CONCLUSIONS:

In patients with ACD and palliative needs, the use of strong opioids continues to prevail in the hospital setting and oncological disease, although pain is highly prevalent in all EOL trajectories and places of care. The high percentage of negative PMI reveals the opportunity for an individualised analgesic ladder stepping for better pain control. Also, incorporating non-pharmacological approaches could help improve pain in these patients.

01 Mar 2025·BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Synthesis and physiological effects of new 4-aminophenol derivatives as paracetamol analogues

Article

Author: Lisouskaya, Maryna ; Antipova, Olga A ; Mikhalchuk, Alexander ; Zhavoronok, Irina P

Paracetamol has antipyretic and analgesic properties and it is widely used for fever and pain. However, paracetamol is partially metabolized to N-acetyl-p-benzoquinoneimine, which in overdose leads to liver necrosis, urging for safer paracetamol analogues. As the latter, new para-aminophenol derivatives containing fragments of acetic acid, saturated fatty acids and monoethanolamine were synthesized. The obtained compounds at equimolar doses of paracetamol (0.5 mmol/kg) have been shown to have modulating effect on thermoregulatory (in experimental fever) and nociceptive (in experimental arthritis) reactions. The studied derivatives in rats with LPS-induced fever leveled the first phase of the febrile response and reduced the increase in core body temperature in the second phase by three times. The synthesized compounds in rats with zymosan-induced arthritis suppressed the nociceptive response in Randall-Selitto test and Hot plate test by 21-48 % and 8-42 %, respectively.

01 Mar 2025·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

A turn-on fluorescent probe for imaging of hydroxyl radicals in drug-induced liver injury

Article

Author: Fu, Wenzhuo ; Yu, Mengshan ; Wang, Yuji ; Xiang, Hanyue ; Taledaohan, Ayijiang ; Xiao, Nao ; Li, Hongyu

Hydroxyl radical is the most oxidizing type of reactive oxygen species (ROS), which is closely related to body health. In this work, a novel turn-on fluorescent probe BIJ-H for OH with high sensitivity was reported. BIJ-H was synthesized by a three-step reaction, and the pure product was obtained by only washing with poor solvents. In a neat aqueous solution containing BIJ-H, after adding OH, the probe was oxidized to BIJ, which produced fluorescence emission at 625 nm under the excitation with 550 nm. This sensing behavior can be achieved under physiological pH conditions. The detection limit of BIJ-H for OH was as low as 0.1379 μM. Thanks to the good analytical properties of BIJ-H, the probe has been applied to fluorescence imaging of OH in HepG2 cells and in acute liver injury induced by acetaminophen. The probe BIJ-H is expected to be used in the qualitative and quantitative detection of OH in physiological or pathological processes.

430

News (Medical) associated with Acetaminophen

24 Dec 2024

·www.drugs.com

Too Much Acetaminophen Could Harm Seniors' Health

TUESDAY, Dec. 24, 2024 -- New British research shows that too much of a good medication can be a bad thing. In the study, repeated doses of paracetamol, known as acetaminophen (brand name Tylenol) in the United States, raised the risk of gastrointestinal, cardiovascular and kidney complications among those over 65. The findings, published recently in the journal Arthritis Care and Research , illustrate the dangers of older people taking too much of the painkiller for chronic, painful conditions such as osteoarthritis. Acetaminophen is used to temporarily relieve mild to moderate pain and fever. It is commonly included as an ingredient in cold and flu medications and is also taken on its own. It works by blocking signals in the brain that let people know when they're in pain and by affecting the chemicals that regulate their body temperature. Evidence also suggests the widely used painkiller inhibits the production of prostaglandins , which are made by the body to deal with illness and injury. Weiya Zhang , from the NIHR Biomedical Research Centre in the School of Medicine at the University of Nottingham, led the study. "Due to its perceived safety, paracetamol [acetaminophen] has long been recommended as the first-line drug treatment for osteoarthritis by many treatment guidelines, especially in older people who are at higher risk of drug-related complications," Zhang noted in a university news release. In the study, researchers analyzed data on over 180,400 people aged 65 and over who had been prescribed acetaminophen repeatedly (more than twice within six months). Their health was then compared to nearly 402,500 people of the same age who had never been prescribed the drug repeatedly. What did they discover? The findings showed that prolonged acetaminophen use was associated with an increased risk of gastrointestinal bleeding (36%); peptic ulcers (20%); heart failure (9%); hypertension (7%); and chronic kidney disease (19%). “Whilst further research is now needed to confirm our findings, given its minimal pain-relief effect, the use of paracetamol as a first-line painkiller for long-term conditions such as osteoarthritis in older people needs to be carefully considered,” Zhang said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

23 Dec 2024

·www.prnewswire.com

Penn Dental Medicine Pain Management Clinical Practice Guideline Among Top Trending Articles in 2024

PHILADELPHIA, Dec. 23, 2024 /PRNewswire/ -- A pain management clinical practice guideline developed by Penn Dental Medicine's Center for Integrative Global Oral Health (CIGOH) is among The Journal of the American Dental Association (JADA)'s top five trending articles for 2024, according to JADA. Originally published in the September 2023 issue of JADA, the guideline for managing acute dental pain in children was developed by CIGOH, the American Dental Association Science and Research Institute (ADASRI), and the University of Pittsburgh School of Dental Medicine. Dr. Alonso Carrasco-Labra, Associate Professor and Director of the Cochrane Oral Health Collaborating Center at Penn Dental Medicine, and Olivia Urquhart, an epidemiologist and instructor within CIGOH, co-led its development. Endorsed by the ADA, the guideline notes that acetaminophen or non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are recommended as first-line treatments for managing short-term dental pain in children under age 12. A guideline panel determined that, when used as directed, acetaminophen alone, NSAIDs (like ibuprofen) alone or acetaminophen in combination with NSAIDS can effectively manage a child's pain after a tooth extraction or during a toothache when dental care is not immediately available. According to the guideline, when acetaminophen or NSAIDs are administered as directed by a dentist or other health care provider, the risk of harm to children from either medication is low. These recommendations align with previous guidance from the U.S. Food and Drug Administration (FDA) in 2017, which contraindicated the use of codeine and tramadol in children under age 12. In 2020, the FDA awarded the University of Pittsburgh and ADASRI a $1.5 million grant to develop a clinical practice guideline for the management of acute pain in dentistry in children, adolescents and adults. A group of researchers and methodologists from ADASRI, the University of Pittsburgh School of Dental Medicine, CIGOH, McMaster University and the Art of Democracy worked together to develop this pediatric patient guideline as well as one for adolescents, adults, and older adults, which published in February 2024. Both guidelines can be found at ada.org/painmanagement. Contact: Beth Adams, [email protected] SOURCE PENN DENTAL MEDICINE WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

19 Dec 2024

·pipelinereview.com

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

— Company Expects to Complete BLA Submission by End of 1Q 2025 — LANGHORNE, PA, USA I December 18, 2024 I Savara Inc. (Nasdaq: SVRA ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, initiated a rolling submission of a BLA to the FDA for MOLBREEVI for the potential treatment of aPAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. MOLBREEVI was granted Fast Track and Breakthrough Therapy Designations in 2019 for the treatment of patients with aPAP. As a result, the Company is allowed to submit individual modules of the BLA as they are completed rather than waiting to submit the application once all modules are available. The Company will request a priority review of the BLA when the submission is completed. “Given the positive results of the pivotal, Phase 3 IMPALA-2 trial, we believe MOLBREEVI demonstrates a favorable benefit-risk profile and could fundamentally change the way aPAP is treated,” said Matt Pauls, Chair and Chief Executive Officer, Savara. “Initiation of the BLA is an important milestone in potentially addressing the unmet need in aPAP, for which there are no approved medicines in the U.S. and Europe. We look forward to working closely with the FDA throughout the review process and expect to complete the submission of the rolling BLA by the end of 1Q 2025.” In addition to Fast Track and Breakthrough Therapy Designations, MOLBREEVI has been granted Orphan Drug Designation for the treatment of aPAP by the FDA and by the European Medicines Agency (EMA), Innovation Passport (IP) and Promising Innovative Medicine (PIM) designations by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA). About Autoimmune PAP Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli (or air sacs) of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in aPAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas exchange, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary lung infection develops. In the long-term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow ® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com , X: @SavaraPharma and LinkedIn . *MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. SOURCE: Savara

Phase 3Fast TrackOrphan DrugBreakthrough TherapyClinical Result

100 Deals associated with Acetaminophen

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00217	Acetaminophen	N02BE01	DB00316

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Headache	US	Cosette Pharmaceuticals, Inc.Startup	09 Feb 1978
Analgesia	JP	Iwaki Seiyaku Co., Ltd.	01 Jul 1966
Fever	CN	Dandong Yichang Pharmaceutical Co., Ltd.	01 Jan 1966
Pain	CN	Dandong Yichang Pharmaceutical Co., Ltd.	01 Jan 1966

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Respiratory Tract Infections	Phase 3	-	GSK Plc	01 Feb 2017
Osteoarthritis	Phase 3	US	GSK Plc	01 Jan 2015
Episodic tension-type headache	Phase 3	US	GSK Plc	01 Apr 2013
Acute Pain	Phase 3	US	Mallinckrodt Plc	01 Jan 2008
Uterine Neoplasms	Phase 3	US	Mallinckrodt Plc	01 Nov 2006
Acute migraine	Phase 3	US	Merck Sharp & Dohme Corp.	01 Mar 2006
Osteoarthritis, Hip	Phase 3	-	McNeil Consumer & Specialty Pharmaceuticals, Inc.	18 Oct 2005
Pain, Postoperative	Phase 3	-	Merck Sharp & Dohme Corp.	01 Jun 2002
Toothache	Phase 3	-	Merck Sharp & Dohme Corp.	01 Jun 2002
Osteoarthritis, Knee	Phase 3	-	Johnson & Johnson Holdco (NA), Inc.	01 Oct 1999

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO_ASIA2024	Not Applicable	Lung Cancer	-	Acetaminophen exposure	mhenhebibk(ginzikgkww) = qirxoractr vxpjrlazaw (cgqmdzhxju )	Positive	07 Dec 2024
NCT04291508 (ASTER, CTgov)	Phase 2	Respiratory Failure \| Critical Illness \| Sepsis ... View more	488	Intravenous Acetaminophen (room temperature) (IV Acetaminophen-Active)	yeacsnmahw(gbtqjessht) = xjttqsfdwy gaplvfalar (mewfixrdwo, moehemfoot - eamqxxftfr) View more	-	27 Sep 2024
				Intravenous Vitamin C (refrigerated) (IV Vitamin C-Active)	yeacsnmahw(gbtqjessht) = dokmylzepy gaplvfalar (mewfixrdwo, wumyiahpem - swwozuaqpu) View more
NCT03859024 (CTgov)	Phase 4	Urethral Stricture \| Pain, Postoperative	48	Acetaminophen+Ibuprofen 800 mg+Oxycodone (Standard Protocol)	duksovsqpx(eqbudktgxv) = qwcihvsciz nbnxhnzgef (hcaojbplst, fvqcrlbkzm - vyyxuwkdev) View more	-	19 Sep 2024
				Acetaminophen+Ibuprofen 800 mg+celebrex+Dexamethasone+Oxycodone+Bupivacaine+Gabapentin (Enhanced Recovery Protocol)	duksovsqpx(eqbudktgxv) = tgdrtntlke nbnxhnzgef (hcaojbplst, lfqzngafur - gpuiywebdb) View more
NCT04879823 (CTgov)	Phase 3	Analgesia	222	Acetaminophen+Ibuprofen+Dexamethasone (Dexamethasone)	mjlgfamvvh(xilevrzfyl) = axorugjujj ilriwpyiyk (qfaqzlqbey, rgtoxgkhmb - taxfqglgux) View more	-	05 Sep 2024
				Placebo+Acetaminophen+Ibuprofen (Placebo)	mjlgfamvvh(xilevrzfyl) = yxjtcdktaj ilriwpyiyk (qfaqzlqbey, xsxcfmoern - ocvgwjbhjp) View more
NCT03929640 (CTgov)	Phase 3	Pain, Postoperative	49	Placebo+Ibuprofen (Ibuprofen and Placebo)	puopqgdtan(zhmrtgzkig) = vufwjuopnb nnqwdhixcx (xmhzugdlfh, xkfrywunff - ehjeheuboj) View more	-	04 Sep 2024
				Acetaminophen+Ibuprofen (Ibuprofen and Acetaminophen)	puopqgdtan(zhmrtgzkig) = dbultamybs nnqwdhixcx (xmhzugdlfh, wqopqqfola - euiwcstizp) View more
NCT04791761 (CTgov)	Phase 1/2	Pain, Postoperative	73	Opioid disposal education+Acetaminophen+Ibuprofen+Oxycodone (Opioid Pain Control)	gsjqnaarij(pzifgxnpki) = uxqwwnowgg hvjtprejwp (pfgkolgwbt, uchjjjdjov - rcpjgmqqha) View more	-	16 Aug 2024
				Acetaminophen+Ibuprofen (Non-opioid Pain Control)	gsjqnaarij(pzifgxnpki) = gsjxgqumqy hvjtprejwp (pfgkolgwbt, vnzfhzibip - yveaxbinni) View more
NCT04015908 (CTgov)	Phase 4	-	100	Pregabalin+Acetaminophen+Celecoxib+Oxycodone (Multi-modal)	atfxsazrub(srhbdqkhfx) = nclvddqcjb ppveuuoiqi (rdnbnkafvf, rrfmtiulal - tcvnobagzd) View more	-	08 Jul 2024
				Percocet (Control)	atfxsazrub(srhbdqkhfx) = jnwbjkgwke ppveuuoiqi (rdnbnkafvf, somearlvwp - bsyqlqotxw) View more
NCT04530149 (CTgov)	Phase 4	Rib Fractures \| Pain	3	Acetaminophen+Bupivacain	msyxpwutaw(jcrysfnkbf) = kkmcrrmbnc rqrxcflgdn (wsttevlhse, egtjifclps - mqgglievct) View more	-	11 Jun 2024
NCT03399318 (Pubmed)	Phase 3	Malaria	256	Aggressive antipyretic therapy (acetaminophen + ibuprofen)	ypabrclcna(jwezbhvuue) = mxbyzxzxrh ybmctuhxeu (gzqfnhfhjf, -0.62) View more	Positive	10 Jun 2024
				Usual care (acetaminophen alone)	ypabrclcna(jwezbhvuue) = doppwsjwoz ybmctuhxeu (gzqfnhfhjf, -0.82 to -0.42) View more